Allison Transmission jumps 10% as options signal fresh bullish conviction

Allison Transmission enters this week having delivered its best five-day performance in months, with the Q3 earnings print acting as the ignition and options positioning now reflecting the most bullish sentiment in at least a year.

The earnings release on November 2 drove a 10.1% one-day gain, the most significant single-day move in the stock's recent history. The stock closed at $118.92 on November 3, up 10.4% on the week and sitting near a price level not seen before the late-October results. The move outpaced most of the peer group: TEX gained 15.8% on the week but that likely reflects its own distinct catalysts, while WAB added only 4.6% and OSK 6.4%, leaving Allison comfortably ahead of the industrial machinery cohort.

The options market is registering the sharpest bullish tilt of the past year. The put/call ratio dropped to 0.28 on November 3, nearly 1.8 standard deviations below its 20-day average of 0.35 and the lowest reading of the past 52 weeks. That is not a defensive hedge, it reflects traders reaching for calls rather than buying protection. For context, the PCR had been running in the 0.37 to 0.41 range throughout October before the earnings catalyst, and the collapse to 0.28 marks a clean break with that pre-announcement posture. Short interest, by contrast, tells a quieter story. At 2.7% of the free float, it has drifted only slightly higher on the week and is down roughly 5% over the past month. With the borrow rate at just 0.47% and availability running at over 2,100% of outstanding short interest, there is no meaningful squeeze dynamic here. Bears are few, borrowing is cheap, and the lending pool is vast.

The Street is warming up further after the print. Morgan Stanley raised its target to $139 from $132 on November 4, maintaining an Equal-Weight rating but clearly acknowledging that the Q3 numbers warranted a higher anchor. Citigroup had already upgraded to Buy in mid-October with a $135 target. JP Morgan trimmed its target to $142 from $145 in early October but held Neutral. Wells Fargo cut to $120 during the same window. The mean consensus target is $140.60, implying roughly 18% upside from current levels, though the spread between the most cautious ($120, Wells Fargo) and the most constructive ($144, Freedom Broker) reflects genuine disagreement about how to price the next leg. Factor scores add nuance: the analyst recommendation differential ranks in the 92nd percentile, indicating unusually positive analyst positioning relative to history, and the EV/EBIT factor ranks in the 85th percentile on value. Forward EPS estimates are also moving in the right direction, with the 12-month forward EPS year-on-year growth factor sitting in the 77th percentile. Where scores are softer, earnings momentum over 30 and 90 days ranks in the 28th to 34th percentile range, a signal that estimate revisions were not building ahead of this beat.

The main ownership story this quarter is a sharp addition from BlackRock. Its latest 13G filing, made on October 27, shows a stake of 9.3% with 7.65 million shares held as of that date, a large jump from the prior period. FMR (Fidelity) remains the largest disclosed holder at 12.8% of shares. No activist 13D filings are on the register. As always with 13D/G disclosures, positions are event-driven around the 5% threshold and reflect the state at the time of filing rather than current holdings.

Insider data, as of August 31, shows net sales of around $4.2 million over the 90 days to that date. CEO David Graziosi exercised options and sold shares in August at prices around $132 to $134, pocketing roughly $3.5 million across those transactions. These were open-market sales without a declared 10b5-1 plan, though the August timing, before the Q3 catalyst, is worth noting. The sales occurred at prices above the current close, which adds some context but does not change the picture materially.

With the next earnings event not until February 12, 2027, the stock's near-term story shifts away from calendar catalysts and toward whether the post-earnings re-rating holds. The key variables to track are whether the options PCR mean-reverts back toward its prior 0.35 to 0.39 range (which would signal the initial enthusiasm fading), whether analyst targets continue to migrate toward the Morgan Stanley and Citigroup levels, and whether short interest, so far unmoved by the bounce, begins to cover or build in response to the new price level.